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1 Introduction
Decision makers, such as doctors, make crucial decisions such as recommending treatments to pa-
tients on a daily basis. Such decisions typically involve careful assessment of the subject’s condition,
analyzing the costs associated with the possible actions, and the nature of the consequent outcomes.
Further, there might be costs associated with the assessment of the subject’s condition itself (e.g.,
physical pain endured during medical tests, monetary costs etc.). Decision makers often leverage
personal experience to make decisions in these contexts, without considering data, even if massive
amounts of it exist. Machine learning models could be of immense help in such scenarios – but these
models would need to consider all three aspects discussed above: predictions of counterfactuals,
costs of gathering information, and costs of treatments. Further, these models must be interpretable
in order to create any reasonable chance of a human decision maker actually using them. In this
work, we address the problem of learning such cost-effective, interpretable treatment regimes from
observational data.
Prior research addresses various aspects of the problem at hand in isolation. For instance, there
exists a large body of literature on estimating treatment effects [5, 12, 4], recommending optimal
treatments [1, 15, 6], and learning intelligible models for prediction [9, 7, 10, 2]. However, an effec-
tive solution for the problem at hand should ideally incorporate all of the aforementioned aspects.
Furthermore, existing solutions for learning treatment regimes neither account for the costs associ-
ated with gathering the required information, nor the treatment costs. The goal of this work is to
propose a framework which jointly addresses all of the aforementioned aspects.
We address the problem at hand by formulating it as a task of learning a decision list that maps
subject characteristics to treatments such that it: 1) maximizes the expectation of a pre-specified
outcome when used to assign treatments to a population of interest 2) minimizes costs associated
with assessing subjects’ conditions and 3) minimizes costs associated with the treatments them-
selves. We propose a novel objective function to learn a decision list optimized with respect to the
criterion highlighted above. We show that the proposed objective is NP-hard. We then optimize
this objective by modeling it as a Markov Decision Process (MDP) and employing a variant of the
Upper Confidence Bound for Trees (UCT) strategy which leverages customized checks for pruning
the search space effectively. Our results on a real world dataset comprised of treatment recommen-
dations for asthma patients demonstrate the effectiveness of the proposed solution.
2 Our Framework
First, we formalize the notion of treatment regimes and discuss how to represent them as decision
lists. We then propose an objective function for constructing cost-effective treatment regimes.
Input Data and Cost Functions. Consider a dataset D = {(x1, a1, y1), (x2, a2, y2) · · ·
(xN , aN , yN)} comprised of N independent and identically distributed observations, each of
which corresponds to a subject (individual), potentially from an observational study. Let xi =
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∈ [V1,V2, · · · Vp] denote the characteristics of subject i. Vf denotes the set of
all possible values that can be assumed by a characteristic f ∈ F = {1, 2, · · ·p}. Each characteristic
f ∈ F can either be a binary, categorical or real valued variable. In the medical setting, example
characteristics include patient’s age, BMI, gender, glucose level etc., Let ai ∈ A = {1, 2, · · ·m}
and yi ∈ R denote the treatment assigned to subject i and the corresponding outcome respectively.
We assume that yi is defined such that higher values indicate better outcomes. For example, the out-
come of a patient can be regarded as a wellness improvement score that indicates the effectiveness
of the assigned treatment.
It can be much more expensive to determine certain subject characteristics compared to others.
For instance, a patient’s age can be easily retrieved either from previous records or by asking the
patient. On the other hand, determining her glucose level requires more comprehensive testing, and
is therefore more expensive in terms of monetary costs, time and effort required both from the patient
as well as the clinicians. We assume access to functions d : F → R, and d′ : A → R which return
the cost of determining any characteristic in F , and the cost of each treatment a ∈ A respectively.
Treatment Regimes. A treatment regime is a function that takes as input the characteristics of any
given subject x and maps them to an appropriate treatment a ∈ A. We employ decision lists to
express treatment regimes as they tend to be intelligible. A decision list is an ordered list of rules
embedded within an if-then-else structure. A treatment regime expressed as a decision list pi is a
sequence of L+ 1 rules [r1, r2, · · · , rL+1]. The last one, rL+1, is a default rule which applies to all
those subjects who do not satisfy any of the previousL rules. Each rule rj (except the default rule) is
a tuple of the form (cj , aj) where aj ∈ A, and cj represents a pattern which is a conjunction of one
or more predicates. Each predicate takes the form (f, o, v) where f ∈ F , o ∈ {=, 6=,≤,≥, <,>},
and v ∈ Vf denotes some value v that can be assumed by the characteristic f (Eg.,‘Age ≥ 40 ∧
Gender=Female”). We define an indicator function, satisfy(xi, cj), which returns a 1 if xi satisfies
cj and 0 otherwise.
The rules in pi partition the dataset D into L + 1 groups: {R1,R2 · · · RL,Rdefault}. A group Rj ,
where j ∈ {1, 2, · · ·L}, is comprised of those subjects that satisfy cj but do not satisfy any of
c1, c2, · · · cj−1. This can be formally written as:
Rj =
{
x ∈ [V1 · · · Vp] | satisfy(x, cj} ∧
j−1∧
t=1
¬ satisfy(x, ct)
}
. (1)
The treatment assigned to each subject by pi is determined by the group that he/she belongs to. More
formally,
pi(xi) =
L∑
l=1
al 1(xi ∈ Rl) + adefault 1(xi ∈ Rdefault) (2)
Similarly, the cost incurred when we assign a treatment to the subject i (treatment cost) according
to the regime pi is given by:
φ(xi) = d
′(pi(xi)) (3)
where the function d′ (defined previously) takes as input a treatment a ∈ A and returns its cost.
We can also define the cost incurred in assessing the condition of a subject i (assessment cost) as per
the regime pi. Note that a subject i belongs to the groupRj if and only if the subject does not satisfy
the conditions c1 · · · cj−1, but satisfies the condition cj (Refer to Eqn. 1). This implies that the
assessment cost incurred for this subject i is the sum of the costs of all the characteristics that appear
in c1 · · · cj . IfNl denotes the set of all the characteristics that appear in c1 · · · cl, the assessment cost
of the subject i as per the regime pi can be written as:
ψ(xi) =
L∑
l=1
[
1(xi ∈ Rl)×
(∑
e∈Nl
d(e)
)]
. (4)
Objective Function. We first formalize the notions of expected outcome, assessment, and treatment
costs of a treatment regime pi with respect to the dataset D.
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If Spiro-Test=Pos and Prev-Asthma=Yes and Cough=High then C
Else if Spiro-Test=Pos and Prev-Asthma =No then Q
Else if Short-Breath =Yes and Gender=F and Age≥ 40 and Prev-Asthma=Yes then C
Else if Peak-Flow=Yes and Prev-RespIssue=No and Wheezing =Yes, then Q
Else if Chest-Pain=Yes and Prev-RespIssue =Yes and Methacholine =Pos then C
Else Q
Figure 1: Regime for treatment recommendations for asthma patients output by our framework; Q
refers to quick-relief, and C corresponds to controller drugs (C is higher cost than Q); Attributes in
blue are least expensive.
The quality of the regime pi is partly determined by the expected outcome when all the subjects in D
are assigned treatments according to pi. The higher the value of such an expected outcome, the better
the quality of the regime pi. There is, however, one caveat to computing the value of this expected
outcome – we only observe the outcome yi resulting from assigning xi to ai in the data D, and not
any of the counterfactuals. To address this problem, we compute the expected outcome of a given
regime pi using doubly robust estimation [11]:
g1(pi) =
1
N
N∑
i=1
∑
a∈A
[
1(ai = a)
ωˆ(xi, a)
{yi − yˆ(xi, a)}+ yˆ(xi, a)
]
1(pi(xi) = a) (5)
ωˆ(xi, a) denotes the probability that the subject i with characteristics xi is assigned to treatment a
in the data D. ωˆ represents the propensity score model. In practice, we fit a multinomial logistic
regression model on D to learn this function. Our framework does not impose any constraints on
the functional form of ωˆ. yˆ corresponds to the outcome regression model and is learned in our
experiments by fitting a linear regression model on D prior to optimizing for the treatment regimes.
The assessment cost of a subject i w.r.t. the regime pi is given in Eqn. 4. The expected assessment
cost across the entire population can be computed as:
g2(pi) =
1
N
N∑
i=1
ψ(xi). (6)
The treatment cost for a subject i who is assigned treatment using regime pi is given in Eqn. 3. The
expected treatment cost across the entire population can be computed as:
g3(pi) =
1
N
N∑
i=1
φ(xi). (7)
The smaller the expected assessment and treatment costs of a regime, the more desirable it is in
practice.
Given the observational data D and a set of all possible combinations of candidate rules C(L), our
objective is to maximize g1(pi), and minimize g2(pi) and g3(pi) :
argmax
pi∈C(L)×A
λ1g1(pi) − λ2g2(pi) − λ3g3(pi). (8)
The λ’s in Eqn. 8 are non-negative weights that scale the relative influence of terms in the objective.
The above objective function is NP-Hard [8]. We model this objective using a Markov Decision
Process and employ a variant of Upper Confidence Bound on Trees (UCT) algorithm which incor-
porates customized strategies for effectively pruning the search space. A proof for NP-Hardness of
Eqn. 8 and a detailed optimization procedure for the same is provided in the Appendix [8].
3 Experimental Evaluation
Here, we discuss the detailed experimental evaluation of our framework. First we analyze the out-
comes obtained and costs incurred when recommending treatments using our approach. Then, we
qualitatively analyze the treatment regime produced by our framework.
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Avg. Avg. Avg. Avg. # of List
Outcome Assess Cost Treat Cost Characs. Len
CITR 74.38 13.87 11.81 7.23 6
IPTL 71.88 18.58 11.83 7.87 8
MCA 70.32 19.53 12.01 10.23 -
OWL (Gaussian) 71.02 25 12.38 16 -
OWL (Linear) 71.02 25 12.38 16 -
Human 68.32 - 12.28 - -
Table 1: Results for Treatment Regimes. Our approach: CITR; Baselines: IPTL, MCA, OWL;
Human refers to the setting where doctors assigned treatments.
Asthma Dataset
# of Data Points 60048
Characteristics age, gender, BMI, BP, short breath, temperature,
cough, chest pain, wheezing, past allergies, asthma history,
family history, has insurance (cost 1)
peak flow test (cost = 2)
spirometry test (cost = 4)
methacholine test (cost = 6)
Treatments & Costs quick relief (cost = 10)
controller drugs (cost = 15)
Outcomes & Scores no asthma attack for ≥ 4 months (score = 100)
no asthma attack for 2 months (score = 66)
no asthma attack for 1 month (score = 33)
asthma attack in less than 2 weeks (score = 0)
Table 2: Summary of dataset.
Dataset. Our dataset (see Table 2) captures details of about 60K asthma patients [7]. For each of
these 60K patients, various attributes such as demographics, symptoms, past health history (cost =
1), test results for peak-flow (cost = 2), spirometry (cost = 4), methacholine (cost = 6) have been
recorded. Each patient in the dataset was prescribed either quick relief medications (cost = 10) or
long term controller drugs (cost = 15). Further, the outcomes in the form of time to the next asthma
attack (after the treatment began) were recorded. The longer this interval, the better the outcome,
and the higher the outcome score.
Baselines. We compared our framework to the following state-of-the-art treatment recommenda-
tion approaches: 1) Outcome Weighted Learning (OWL) [17] 2) Modified Covariate Approach
(MCA) [14] 3) Interpretable and Parsimonious Treatment Regime Learning (IPTL) [16]. While
none of these approaches explicitly account for treatment costs or costs required for gathering the
subject characteristics, MCA and IPTL minimize the number of characteristics/covariates required
for deciding the treatment of any given subject. OWL, on the other hand, often uses all the charac-
teristics available in the data when assigning treatments.
Quantitative Analysis. We analyzed the performance of our approach CITR (Cost-effective, In-
terpretable Treatment Regimes) w.r.t. various metrics such as: average outcome obtained (Avg.
Outcome), average assessment and treatment costs (Avg. Assess Cost, Avg. Treat Cost), average
no. of characteristics (Avg. # of Characs.) used to determine treatment of any given patient, and
number of rules in the rule list (List Len). These results are shown in Table 1. It can be seen that the
treatment regimes produced by our approach results in better average outcomes with lower costs. It
is also interesting that our approach produces more concise lists with fewer rules compared to the
baselines. While the treatment costs of all the baselines are similar, there is some variation in the av-
erage assessment costs and the outcomes. IPTL turns out to be the best performing baseline in terms
of the average outcome, average assessment costs, and average number of characteristics. The last
line of Table 1 shows the average outcomes and the average treatment costs computed empirically
on the observational data.
Qualitative Analysis. The treatment regime produced by our approach on the asthma dataset is
shown in Figure 1. It can be seen that methacholine test, which is more expensive, appears at the
end of the regime. This ensures that only a small fraction of the population (8.23%) is burdened by its
cost. Furthermore, it turns out that though the spirometry test is slightly more expensive than patient
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demographics and symptoms, it would be harder to determine the treatment for a patient without
this test. This aligns with research on asthma treatment recommendations [13, 3]. Furthermore, it is
interesting to note that the regime not only accounts for test results on spirometry and peak flow but
also assesses if the patient has a previous history of asthma or respiratory issues.
4 Conclusions
In this work, we proposed a framework for learning cost-effective, interpretable treatment regimes
from observational data. To the best of our knowledge, this is the first solution to the problem
at hand that addresses all of the following aspects: 1) maximizing the outcomes 2) minimizing
treatment costs, and costs associated with gathering information required to determine the treatment
3) expressing regimes using an interpretable model. We modeled the problem of learning a treatment
regime as a MDP and employed a variant of UCT which prunes the search space using customized
checks. We demonstrated the effectiveness of our framework on real world data from health care
domain.
References
[1] E.-M. Abulesz and G. Lyberatos. Novel approach for determining optimal treatment regimen for cancer
cemotherapy. International journal of systems science, 19(8):1483–1497, 1988.
[2] J. Bien and R. Tibshirani. Classification by set cover: The prototype vector machine. arXiv preprint
arXiv:0908.2284, 2009.
[3] L.-P. Boulet, M.- `E. Boulay, G. Gauthier, L. Battisti, V. Chabot, M.-F. Beauchesne, D. Villeneuve, and
P. Coˆte´. Benefits of an asthma education program provided at primary care sites on asthma outcomes.
Respiratory medicine, 109(8):991–1000, 2015.
[4] J. A. Dorresteijn, F. L. Visseren, P. M. Ridker, A. M. Wassink, N. P. Paynter, E. W. Steyerberg, Y. van der
Graaf, and N. R. Cook. Estimating treatment effects for individual patients based on the results of ran-
domised clinical trials. Bmj, 343:d5888, 2011.
[5] R. B. D’Agostino. Estimating treatment effects using observational data. Jama, 297(3):314–316, 2007.
[6] A. Fan, W. Lu, R. Song, et al. Sequential advantage selection for optimal treatment regime. The Annals
of Applied Statistics, 10(1):32–53, 2016.
[7] H. Lakkaraju, S. H. Bach, and J. Leskovec. Interpretable decision sets: A joint framework for description
and prediction. In KDD, 2016.
[8] H. Lakkaraju and C. Rudin. Learning cost-effective treatment regimes using markov decision processes.
https://arxiv.org/abs/1610.06972, 2016.
[9] B. Letham, C. Rudin, T. H. McCormick, D. Madigan, et al. Interpretable classifiers using rules and
bayesian analysis: Building a better stroke prediction model. The Annals of Applied Statistics, 9(3):1350–
1371, 2015.
[10] Y. Lou, R. Caruana, and J. Gehrke. Intelligible models for classification and regression. In Proceedings
of the 18th ACM SIGKDD international conference on Knowledge discovery and data mining, pages
150–158. ACM, 2012.
[11] J. K. Lunceford and M. Davidian. Stratification and weighting via the propensity score in estimation of
causal treatment effects: a comparative study. Statistics in medicine, 23(19):2937–2960, 2004.
[12] J. J. McGough and S. V. Faraone. Estimating the size of treatment effects: moving beyond p values.
Psychiatry (1550-5952), 6(10), 2009.
[13] J. Pereira, P. Porto-Figueira, C. Cavaco, K. Taunk, S. Rapole, R. Dhakne, H. Nagarajaram, and J. S.
Caˆmara. Breath analysis as a potential and non-invasive frontier in disease diagnosis: an overview.
Metabolites, 5(1):3–55, 2015.
[14] L. Tian, A. A. Alizadeh, A. J. Gentles, and R. Tibshirani. A simple method for estimating interactions
between a treatment and a large number of covariates. Journal of the American Statistical Association,
109(508):1517–1532, 2014.
[15] M. P. Wallace and E. E. Moodie. Personalizing medicine: a review of adaptive treatment strategies.
Pharmacoepidemiology and drug safety, 23(6):580–585, 2014.
[16] Y. Zhang, E. B. Laber, A. Tsiatis, and M. Davidian. Using decision lists to construct interpretable and
parsimonious treatment regimes. Biometrics, 71(4):895–904, 2015.
[17] Y. Zhao, D. Zeng, A. J. Rush, and M. R. Kosorok. Estimating individualized treatment rules using
outcome weighted learning. Journal of the American Statistical Association, 107(499):1106–1118, 2012.
5
